BioAtla has presented first-in-human Phase I study data of its anti-cancer therapy, BA3182, targeting those with ...

In a recent regulatory development, the Subject Expert Committee (SEC) under the Dermatology and Allergy division of the ...

Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.

Nuravax, Institute for Molecular Medicine to present phase 1 results & phase 2 design of Alzheimer’s vaccine AV-1959R at CTAD 2025: Irvine, California Friday, July 4, 2025, 17:0 ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Panelists discuss how current multiple sclerosis (MS) therapies show limited effectiveness against progression, but emerging ...

CytoDyn announces encouraging clinical findings among patients with advanced metastatic colorectal cancer previously treated with leronlimab: Vancouver, Washington Friday, July 4, ...

Mack Roach III, MD, discusses the development and evaluation of a multimodal AI algorithm designed to predict prostate cancer outcomes and its performance across racial subgroups.

Invest confidently with Healthpeak (DOC) stock. See here for insights on strong buy potential, stable yield, and portfolio ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...